Florian Weiland

Dr. Florian Weiland


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2009 in Electrophoresis
Verified
Journal Article
Closed access
PDF file
AGAngelika Görg
Angelika Görg
ODOliver Drews
Oliver Drews
CLCarsten Lück
Carsten Lück
FWFlorian Weiland
Florian Weiland
WWWalter Weiss
Walter Weiss

19 February 2015 in Proteomics – Clinical Applications
Verified
Journal Article
Closed access
PDF file
GAGeorgia Arentz
Georgia Arentz
FWFlorian Weiland
Florian Weiland
MOMartin K. Oehler
Martin K. Oehler
PHPeter Hoffmann
Peter Hoffmann

28 September 2018 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
IMIvan M Muñoz
Ivan M Muñoz
MMMichael E Morgan
Michael E Morgan
JPJulien Peltier
Julien Peltier
FWFlorian Weiland
Florian Weiland
MGMateusz Gregorczyk
Mateusz Gregorczyk
JRJohn Rouse
John Rouse
Mutations in the gene encoding the protein kinase CDKL5 cause a debilitating neurodevelopmental disease termed CDKL5 disorder. The impact of these mutations on CDKL5 function is poorly understood because the substrates and cellular processes controlled by CDKL5 are unclear. Here, we describe a quantitative phosphoproteomic screening which identified MAP1S, CEP131 and DLG5—regulators of microtubule and centrosome function—as cellular substrates of CDKL5. Antibodies against MAP1S phospho‐Ser 900 and CEP131 phospho‐Ser 35 confirmed CDKL5‐dependent phosphorylation of these targets in human cells. The phospho‐acceptor serine residues in MAP1S, CEP131 and DLG5 lie in the motif RPX S A, although CDKL5 can tolerate residues other than Ala immediately C‐terminal to the phospho‐acceptor serine. We provide insight into the control of CDKL5 activity and show that pathogenic mutations in CDKL5 cause a major reduction in CDKL5 activity in vitro and in cells. These data reveal the first cellular substrates of CDKL5, which may represent important biomarkers in the diagnosis and treatment of CDKL5 disorder, and illuminate the functions of this poorly characterized kinase.

1 May 2014 in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
Verified
Journal Article
Closed access
JHJulia M. Humphries
Julia M. Humphries
MPMegan Penno
Megan Penno
FWFlorian Weiland
Florian Weiland
MKManuela Klingler-Hoffmann
Manuela Klingler-Hoffmann
AZAgnieszka Zuber
Agnieszka Zuber
PHPeter Hoffmann
Peter Hoffmann

17 May 2016 in Proteomics
Verified
Journal Article
Open access
PDF file
KSKlaus Oliver Schubert
Klaus Oliver Schubert
FWFlorian Weiland
Florian Weiland
BBBernhard T. Baune
Bernhard T. Baune
PHPeter Hoffmann
Peter Hoffmann
Matrix‐assisted laser desorption/ionization mass spectrometry imaging (MALDI‐MSI) is a mass spectrometry technique used for the analysis of macromolecules on an intact tissue of interest, thereby allowing the assessment of molecular signatures in health and disease in the anatomical context. MALDI‐MSI is increasingly used to investigate neurodegenerative and psychiatric disorders at the molecular level, including Alzheimer's disease (AD), Parkinson's disease (PD), and schizophrenia (SCZ). These illnesses are characterized by complex neuropathological processes, and conventional proteomic techniques investigating brain tissue homogenates have inherent limitations in determining the precise anatomical or cellular location of proteomic findings. In this article, we review MALDI‐MSI studies on neurodegenerative and psychiatric disorders, and explore whether the technique could accelerate the translation of proteomic information into improved understanding and ultimately better therapeutic applications.

26 May 2009
Verified
Book Chapter
Closed access
PDF file
WWWalter Weiss
Walter Weiss
FWFlorian Weiland
Florian Weiland
AGAngelika Görg
Angelika Görg